Press Release: Sanofi Completes Acquisition of Blueprint Medicines

Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint...

Sanofi Completes Acquisition of Blueprint Medicines - USA Herald

In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its acquisition of U.S.-based Blueprint Medicines Corp., closing a deal worth up to $9.5 billion and sending a clear message that it’s doubling down on its rare disease and immunology bets. The French pharmaceutical titan, advised by Weil Gotshal & Manges LLP, confirmed that all conditions of the tender offer have been satisfi…

Sanofi Finalizes Blueprint Medicines Deal Adding Ayvakit and Robust SM Pipeline

Open the article to view the coverage from EuropaWire.eu

Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes

Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were no more able than those on placebo to go three months ...

Sanofi completes acquisition of Blueprint Medicines

PARIS — Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologist…